Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, (Q87485618)
Jump to navigation
Jump to search
scientific article published on 25 June 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, |
scientific article published on 25 June 2016 |
Statements
Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry (English)
J Zweegers
J M P A van den Reek
P C M van de Kerkhof
M E Otero
A L A Kuijpers
M I A Koetsier
W P Arnold
M A M Berends
L Weppner-Parren
P M Ossenkoppele
M D Njoo
J M Mommers
P P M van Lümig
R J B Driessen
W Kievit
E M G J de Jong